Bisphosphonates in Bone Disease 2000
DOI: 10.1016/b978-012260371-6/50013-6
|View full text |Cite
|
Sign up to set email alerts
|

Other diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
3

Year Published

2001
2001
2018
2018

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 0 publications
0
3
0
3
Order By: Relevance
“…Hydroxyapatite (HAP) and Bone Affinity. The effects of BPs on calcium-related disorders are principally due to their interaction with osteoclasts and osteoblasts after the formation of stable complexes with calcium of HAP present at the sites of new bone formation . To evaluate the affinity for hydroxyapatite, the BPs were dissolved in 0.05 M Tris buffer and subsequently incubated with HAP, according to a procedure described elsewhere .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Hydroxyapatite (HAP) and Bone Affinity. The effects of BPs on calcium-related disorders are principally due to their interaction with osteoclasts and osteoblasts after the formation of stable complexes with calcium of HAP present at the sites of new bone formation . To evaluate the affinity for hydroxyapatite, the BPs were dissolved in 0.05 M Tris buffer and subsequently incubated with HAP, according to a procedure described elsewhere .…”
Section: Resultsmentioning
confidence: 99%
“…These products are considered analogues of pyrophosphate ( 2 , Chart ). They contain the P−C−P substructure, which is resistant to chemical and enzymatic hydrolysis, while P−O−P is a susceptible hydrolysis moiety . As a result of their ability to chelate calcium ions by bidentate or tridentate binding, bisphosphonates display a high affinity to the bone mineral surface where they accumulate because they cannot be degraded metabolically.…”
Section: Introductionmentioning
confidence: 99%
“…Bisphosphonates are very important inhibitors of osteoclastic bone resorption in vivo [24] and are used in diseases such as osteoporosis, hypercalcemia of malignancy, Paget's disease of bone, and osteolytic bone disease [2527]. However, up to now there had not been any indications for the use of these drugs in the treatment of ON.…”
Section: Discussionmentioning
confidence: 99%
“…Найбільш поширений постменопаузальний ОП, частота якого коливається від 35,8 до 55 %, а у віці до 80 років майже у 70 % жінок спостерігається значне зниження МЩКТ, що пов'язано з дефіцитом естрогенів в постменопаузі, більш низьким піком кісткової маси [2,3]. Втрата кісткової маси у жінок починається приблизно у 35-40 років і становить 0,5-1 % за рік, а з настанням постменопаузи цей показник збільшується до 3-7 % на рік [3,6]. Таким чином, в перші роки постменопаузи жінка може втратити до 9-35 % кісткової маси.…”
unclassified
“…Серед групи антиостеопоротичних препаратів слід звернути увагу на бісфосфонати -БФ [1,6,9]. Іх застосовують для терапії всіх типів і форм ОП, але найчастіше при лікуванні постменопаузального ОП.…”
unclassified